[go: up one dir, main page]

EP1000045A1 - Piperazines 1,4-disubstituees - Google Patents

Piperazines 1,4-disubstituees

Info

Publication number
EP1000045A1
EP1000045A1 EP98945130A EP98945130A EP1000045A1 EP 1000045 A1 EP1000045 A1 EP 1000045A1 EP 98945130 A EP98945130 A EP 98945130A EP 98945130 A EP98945130 A EP 98945130A EP 1000045 A1 EP1000045 A1 EP 1000045A1
Authority
EP
European Patent Office
Prior art keywords
piperazine
pyridyl
group
aminoethyl
cyclohexylcarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98945130A
Other languages
German (de)
English (en)
Inventor
Amedeo Leonardi
Gianni Motta
Carlo Riva
Luciano Guarneri
Elena Poggesi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Recordati Industria Chimica e Farmaceutica SpA
Original Assignee
Recordati SA
Recordati Industria Chimica e Farmaceutica SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI971863 external-priority patent/IT1293806B1/it
Priority claimed from ITMI971862 external-priority patent/IT1293805B1/it
Application filed by Recordati SA, Recordati Industria Chimica e Farmaceutica SpA filed Critical Recordati SA
Publication of EP1000045A1 publication Critical patent/EP1000045A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to novel 1 ,4-disubstituted piperazines that bind to serotonergic receptors, to pharmaceutical compositions containing them, and to uses for such derivatives and compositions.
  • micturition In mammals, micturition (urination) is a complex process that requires the integrated actions of the bladder, its internal and external sphincters, the musculature of the pelvic floor, and neurological control over these muscles at three levels (in the bladder wall or sphincter itself, in the autonomic centres of the spinal cord, and in the central nervous system at the level of the pontine micturition centre (PMC) in the brainstem (pons) under the control of cerebral cortex) (De Groat, Neurobiology of Incontinence, (Ciba Foundation Symposium 151:27, 1990).
  • Micturition results from contraction of the detrusor muscle, which consists of interlacing smooth muscle fibres under parasympathetic autonomic control from the sacral spinal cord.
  • a simple voiding reflex is formed by sensory nerves for pain, temperature, and distension that run from the bladder to the sacral cord.
  • sensory tracts from the bladder also reach the PMC, resulting in the generation of nerve impulses that normally suppress the sacral spinal reflex arc controlling bladder emptying.
  • normal micturition is initiated by voluntary suppression of cortical inhibition of the reflex arc and by relaxation of the muscles of the pelvic floor and the external sphincter.
  • the detrusor muscle contracts and voiding occurs.
  • Abnormalities of lower urinary tract function e.g., dysuria, incontinence, and enuresis, are common in the general population.
  • Dysuria includes urinary frequency, nocturia, and urgency, and may be caused by cystitis, prostatitis or benign prostatic hypertrophy (BPH) (which affects about 70% of elderly males), or by neurological disorders.
  • Incontinence syndromes include stress incontinence, urgency incontinence, and overflow incontinence.
  • Enuresis refers to the involuntary passage of urine at night or during sleep.
  • treatment of neuromuscular dysfunction of the lower urinary tract has involved administration of compounds that act directly on the bladder muscles, such as flavoxate, a spasmolytic drug (Ruffman, J. Int.Med.Res.
  • the compounds of the present invention are structurally different from compound A because of the novel substitutions on the aromatic ring bound to the piperazine moiety and of the insertion of a series of spacers (Z) between the piperazine and phenyl rings.
  • These structural variations are not disclosed by GB 2255337 A, particularly with regard to compounds that can be used to improve urinary tract function.
  • These novel compounds also have a longer duration of action than does A in pharmacological tests predictive of activity on the lower urinary tract. This is especially true with respect to the activity of the compounds of the invention against urinary incontinence, which is a novel therapeutic indication for this class of compounds acting at the 5-HTj A receptor.
  • the invention relates to the use of compounds of formula I:
  • n 1 or 2.
  • Het represents a monocyclic heteroaryl group
  • R represents a cycloalkyl or a monocyclic heteroaryl group
  • R 3 represents a hydrogen atom or a lower alkyl group
  • Z represents a bond or a group of the formula -CH 2 -, -CH 2 CH 2 -, -CH 2 C(O)-, -CH 2 CH(OH)-, -O-, -OCH 2 - or -C(O)-, each of which is depicted with its left end being the end which attaches to the piperazine ring and its right end being the end which attaches to group B, and B represents a substituted or unsubstituted aryl or heteroaryl radical, for the preparation of a medicament for the treatment of neuromuscular dysfunction of the lower urinary tract in a mammal.
  • R represents a hydrogen or halogen atom or an alkoxy. nitro, amino, acylamino or alkylsulphonylamino group, and
  • R 2 represents a halogen atom or an alkoxy, polyfluoroalkoxy. cyano or carbamoyl group, but if R, does not represent an acylamino or alkylsulphonylamino group, then R 2 represents a polyfluoroalkoxy group; and the compounds I in which Z represents a group of the formula -CH 2 -, -CH 2 CH 2 -,
  • -CH 2 C(O)-, -CH 2 CH(OH)-, -O-, -OCH 2 - or -C(O)- are new and are provided in another aspect of the invention.
  • the invention also includes the enantiomers, diastereomers, N-oxides, crystalline forms, hydrates and pharmaceutically acceptable salts of these compounds, as well as metabolites of these compounds having the same type of activity (hereafter sometimes referred to as
  • the invention further provides pharmaceutical compositions comprising a compound of formula I or an enantiomer, diastereomer, N-oxide, crystalline form, hydrate or pharmaceutically acceptable salt of the compound, in admixture with a pharmaceutically acceptable diluent or carrier.
  • the compounds of the invention are useful for reducing the frequency of bladder contractions due to bladder distension by administering one or more selected compounds of Formula I to a mammal (including a human) in need of such treatment, in an amount or amounts effective for the particular use.
  • the compounds of the invention are also useful for treating disorders of the urinary tract in a subject in need of such treatment, by administering an amount of a compound of Formula 1 effective to ameliorate at least one of urinary urgency, increased urinary frequency, incontinence, urine leakage, enuresis, dysuria, urinary hesitancy, and difficulty in emptying the bladder.
  • the compounds of the invention have been found to bind to 5-HTiA serotonergic receptors and, by virtue of this activity, may be found useful for the treatment of CNS disorders due to serotonergic dysfunction.
  • Such dysfunctions include anxiety, depression, hypertension, sleep/wake cycle disorders, feeding behaviour, sexual function and cognition disorders in mammals, particularly in humans.
  • Treatment may be effected by delivering to the environment of the 5-HT J A serotonergic receptors, e.g., to the extracellular medium (or by administering to a mammal possessing such receptors), an effective amount of a compound of the invention.
  • the activity of the compounds of the invention as inhibitors of frequency of micturition renders them useful for the treatment of neuromuscular dysfunctions of the lower urinary tract in mammals, including without limitation dysuria, incontinence and enuresis.
  • cycloalkyl groups R are C5-C7 cycloalkyl groups; preferred monocyclic heteroaryl groups R and Het are those having 5 to 7 ring atoms including one or more hetero atoms (e.g. oxygen, nitrogen, or sulphur).
  • Lower alkyl as used herein, includes Ci to C6 alkyl.
  • Alkyl when used in, for example "alkylsulphonylamino", also means lower alkyl, preferably Ci to C alkyl.
  • Preferred heteroaryl groups B are mono or bicyclic aromatic radical having from 5 to 12 ring atoms including one or more heteroatoms (e.g. nitrogen, oxygen, sulphur).
  • n 1
  • R represents a cyclohexyl group
  • Het represents a 2-pyridyl group
  • R 3 represents a hydrogen atom, all independently of each other.
  • a preferred group of compounds is that in which Z represents a bond.
  • R represents a hydrogen or halogen atom or a nitro, amino, acylamino or alkylsulphonylamino group
  • R 2 represents an alkoxy, trifluoroalkoxy, cyano or carbamoyl group.
  • Z represents a bond and B represents a 2-trifluoromethoxyphenyl, 2-(2,2,2- trifluoroethoxy)-phenyl, 5-chloro-2-(2,2,2-trifluoroethoxy)-phenyl, 4-acetamido-2- methoxyphenyl, 2-methoxy-4-methylsulphonylamino-phenyl, 2-methoxy-4- pivaloylaminophenyl or 4-butanoylamino-2 -methoxyphenyl group.
  • B preferably represents an unsubstituted phenyl group or a substituted phenyl group, the substituents being selected from halogen atoms and alkoxy, cyano, nitro, amino, acylamino, alkylsulphonylamino, polyfluoroalkoxy and carbamoyl groups.
  • Another preferred group of compounds is that in which Z represents a group of the formula -CH 2 -, -CH 2 CH 2 -, -CH 2 C(O)-, -CH 2 CH(OH)- or -C(O)-.
  • a still further preferred group of compounds is that in which Z does not represent a valence bond and in which B represents a phenyl, 2,5-dichlorophenyl or 2-bromo-5-methoxyphenyl group.
  • Subjects who can benefit from administration of the compounds and compositions of the invention include humans who are affected by neuromuscular dysfunction of the lower urinary tract, described by E.J. McGuire in "Campbell's UROLOGY” 5 th Ed. 616-638, 1986, W.B. Saunders Company, and also include patients affected by any physiological dysfunction related to impairment of 5-HTI A receptor function. Such dysfunctions include, without limitation, central nervous system disorders such as depression, anxiety, eating disorders, sexual dysfunction, addiction, and related problems.
  • the present invention encompasses pharmaceutical formulations comprising the compounds disclosed above, as well as methods employing these formulations for treating neuromuscular dysfunction of the lower urinary tract such as dysuria, incontinence, enuresis, and the like.
  • Dysuria includes urinary frequency, nocturia, urgency, and difficulty in emptying the bladder, i.e., a suboptimal volume of urine is expelled during micturition.
  • Incontinence syndromes include stress incontinence, urgency incontinence, and overflow incontinence.
  • Enuresis refers to the involuntary passage of urine at night or during sleep. Without wishing to be bound by theory, it is believed that administration of 5-HTIA receptor antagonists prevents unwanted activity of the sacral reflex arc and/or cortical mechanisms that control micturition. Thus it is contemplated that a wide range of neuromuscular dysfunctions of the lower urinary tract can be treated using the compounds of the present invention.
  • An "effective amount" of the compound for treating a urinary disorder is an amount that results in measurable amelioration of at least one symptom or parameter of the disorders described above.
  • An effective amount for treating the disorder can easily be determined by empirical methods known to those of ordinary skill in the art, such as by establishing a matrix of dosages and frequencies of administration and comparing a group of experimental units or subjects to each point in the matrix.
  • the exact amount to be administered to a patient will vary depending on the state and severity of the disorder and the physical condition of the patient.
  • a measurable amelioration of any symptom or parameter can be determined by a physician skilled in the art or reported by the patient to the physician. It will be understood that any clinically or statistically significant attenuation or amelioration of any symptom or parameter of urinary tract disorders is within the scope of the invention.
  • Clinically significant attenuation or amelioration means perceptible to the patient and/or to the physician.
  • a single patient may suffer from several symptoms of dysuria simultaneously, such as, for example, urgency and excessive frequency of urination, either or both of which may be reduced using the methods of the present invention.
  • urgency and excessive frequency of urination either or both of which may be reduced using the methods of the present invention.
  • any reduction in the frequency or volume of unwanted passage of urine is considered a beneficial effect of the present methods of treatment.
  • the compounds of the present invention may be formulated into liquid dosage forms with a physiologically acceptable carrier, such as, for example, phosphate buffered saline or deionized water.
  • a physiologically acceptable carrier such as, for example, phosphate buffered saline or deionized water.
  • the pharmaceutical formulation may also contain excipients, including preservatives and stabilisers, that are well-known in the art.
  • the compounds can be formulated into solid oral or non-oral dosage units such as, for example, tablets, capsules, powders, and suppositories, and may additionally include excipients, including without limitation lubricant(s), plasticizer(s), colorant(s), absorption enhancer(s), bactericide(s), and the like. Modes of administration include oral and enteral.
  • an oral or transdermal route is used (i.e., via solid or liquid oral formulations, or skin patches, respectively).
  • the amount of the agent to be administered can range from between about 0.01 and about 25 mg/kg/day, preferably from between about 0.1 and about 10 mg/kg/day and most preferably from between about 0.2 and about 5 mg/kg/day. It will be understood that the pharmaceutical formulations of the present invention need not in themselves contain the entire amount of the agent that is effective in treating the disorder, as such effective amounts can be reached by administration of a plurality of doses of such pharmaceutical formulations.
  • compounds are formulated in capsules or tablets, each preferably containing 50-200 mg of the compounds of the invention, and are most preferably administered to a patient at a total daily dose of 50-400 mg, preferably 150-250 mg, and most preferably about 200 mg for relief of urinary incontinence and dysfunctions amenable to treatment with 5-HTJA receptor ligands.
  • the intermediates of formula II can be converted into intermediates with formula III by conventional acylation procedures known to those skilled in the art, e.g., by using acylating reagents of the formula X-CH(R3)-(CH2)n-l-C(O)-X ⁇ , where X is a leaving group, e.g. Br, CI, I, p-toluenesulphonyloxy, methylsulphonyloxy and X], for example, is Br, CI, OH, and the like.
  • Intermediates with formula III can be condensed by conventional methods with the piperazine derivatives IV, in the presence of a base, to afford Intermediates with formula V.
  • the acylation can be performed by conventional procedures, known to those of ordinary skill.
  • Xi of the acylating agent is OH
  • the amine-substituted heteroaroma ic can be acylated by the addition of a coupling agent (e.g. diethyl cyanophosphonate, dicyclohexylcarbodiimide or N,N'-carbonyldiimidazole) optionally in the presence of a promoting agent (e.g. N-hydroxysuccinimide, 4-dimethylaminopyridine) in an aprotic or a chlorinated solvent (e.g.
  • a coupling agent e.g. diethyl cyanophosphonate, dicyclohexylcarbodiimide or N,N'-carbonyldiimidazole
  • a promoting agent e.g. N-hydroxysuccinimide, 4-dimethylaminopyridine
  • reaction procedures for acylation of amines include the mixed anhydride method by reaction of intermediates with formula VII with an alkyl chloroformate in the presence of a tertiary amine (e.g. triethylamine) followed by addition of the heteroarylamine reagent in an aprotic solvent (e.g. dioxane, methylene chloride), optionally in the presence of, e.g. 1 -hydroxypiperidine as a promoting agent (Org. React. 1962, 12, 157).
  • aprotic solvent e.g. dioxane, methylene chloride
  • Intermediates with formula V can be then reduced to intermediates of formula VI by the use of reducing agents which can convert the amido functionality into an amino group.
  • reducing agents include complex metal hydrides, e.g. lithium aluminium hydride in diethyl ether or tetrahydrofuran, or a stable diborane complex such as borane-tetrahydrofuran or borane-dimethyl sulphide, or the like (J. Org. Chem 1982, 47, 1389) used in a solvent suitable for reducing reactions, e.g. tetrahydrofuran.
  • Z is CH 2 C( ⁇ )
  • these reduction procedures can in any case be applied if the keto group is previously protected by procedures which are well-known to those of ordinary skill in the art.
  • the reaction can be carried out in a polar aprotic solvent such as pyridine, DMF, toluene, etc., at temperatures between +40°C and +120°C, optionally in the presence of a base such as ET.3N.
  • a strong base e.g. n-butyl lithium, lithium diisopropylamide, lithium hexamethyldisilylamide, sodium hydride, sodium amide
  • apolar or polar aprotic solvents e.g. toluene, THF.
  • reaction components include acidic promoters such as acetic acid.
  • the reactions proceed at temperatures between +10°C and 100°C.
  • carbonyl compounds of formula XI may be reacted with an appropriate N-protected piperazine of formula XII, using the same reductive conditions described above, to give intermediates with structure XIII.
  • Reactions can be carried out in polar aprotic solvents such as N,N-dimethylformamide (DMF), tetrahydrofuran (THF), dioxane, acetone, acetonitrile or chlorinated solvents such as dichloromethane, or chloroform, at temperatures between 0°C and 120°C.
  • the reactions are typically performed in the presence of a proton acceptor such as triethylamine (Et3N), diisopropylethylamine, and the like, and optionally in the presence of potassium iodide.
  • a proton acceptor such as triethylamine (Et3N), diisopropylethylamine, and the like, and optionally in the presence of potassium io
  • X and Xi can be chloro, bromo, iodo, alkyl- or arylsulphonyloxy.
  • phosphine ligand e.g. triphenylphosphine or tri-o-tolyl- phosphine or bis(diphenylphosphino)ferrocene or 2,2'-bis(diphenylphosphino)- 1,1 '-binaphthyl or other commercially available phosphine ligands.
  • phosphine ligand e.g. triphenylphosphine or tri-o-tolyl- phosphine or bis(diphenylphosphino)ferrocene or 2,2'-bis(diphenylphosphino)- 1,1 '-binaphthyl or other commercially available phosphine ligands.
  • alkylations may be carried out in a chlorinated solvent such as dichloromethane, chloroform or 1 ,2-dichloroethane, or in a polar aprotic solvent such as DMF, THF, acetone, acetonitrile, «-butanol, etc., or in an apolar solvent such as toluene, benzene, «-heptane, and the like, at temperatures between 0 °C and 120 °C.
  • the reaction mixture can, optionally, contain a proton acceptor such as Et3N, 4-dimethylaminopyridine, potassium carbonate, caesium carbonate, and the like.
  • the reaction can also optionally be performed in the presence of potassium iodide.
  • Such reactions may be carried out at the melting temperature of the reactants without solvent, or in an aprotic solvent such as dichloromethane, chloroform. DMF. THF, acetone, acetonitrile, or a protic one such as ⁇ -butanol. and the like at temperatures between 0°C and +160°C.
  • the reactions can.
  • Diethyl ether, THF, methanol, ethanol, dioxane and solvent mixtures thereof that are suitable for use with strong bases and reducing agents may be used as reaction solvents, at temperatures between +10°C and the reflux temperature of the solvent.
  • these reductions may be carried out to achieve compounds of formula I where Z is CH2C(O) by employing lithium tri-t-butoxyaluminium hydride (Endy L., J. Org. Chem. 35, 549 (1970)) or other selective reducing agents.
  • the compounds of formula I where Z is O or OCH2 and B is aryl may be prepared from the corresponding N-oxide derivatives of compounds I in which Z is a bond or CH2 by thermal rearrangement (Meisenheimer isomerization):
  • a base e.g. triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, potassium carbonate
  • a base e.g. triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, potassium carbonate
  • a base e.g.
  • a proper aprotic solvent such as toluene, tetrahydrofuran, dimethoxyethane, dioxane, diglyme or others
  • the compounds of the invention of formula la wherein Rj is nitro can be easily converted into compounds of formula I where Ri is amino, acylamino, or alkylsulfonylamino by conventional reaction procedures, such as by reduction of the nitro group via catalytic hydrogenation, transfer hydrogenation or well-known chemical methods to afford amino compounds with formula I, which can be then properly acylated or methylsulphonylated by known methods.
  • Rj is nitro
  • the title compound was prepared as described in the final step of Example 1 , but using l-(2-cyanophenyl)-piperazine [prepared as described by Martin et al, in J. Med. Chem., 32, 1052 (1996)] in place of l-(2-trifluoromethoxyphenyl)-piperazine.
  • the obtained residue was purified by flash chromatography (ethyl acetate : petroleum ether, gradient 90:10 to 10:0). Evaporation of the solvents afforded the title compound, yield 19.5%.
  • EXAMPLE 6 l-rN-cvclohexylcarbonyl-N-(2-pyridv ⁇ -2-aminoethyll-4-(4-amino-2-methoxyphenyl)- piperazine A mixture of 1.70 g of l-[N-cyclohexylcarbonyl-N-(2-pyridyl)-2-aminoethyl]-4-(4- nitro-2-methoxyphenyl)-piperazine (prepared as described in Example 5), 18 ml of tetrahydrofuran, 18 ml of methanol, 50 mg of Raney Nickel and 1 ml of hydrazine hydrate was stirred for 2 hours at room temperature.
  • EXAMPLE 7 l-[N-cvclohexylcarbonyl-N-(2-pyridyl)-2-aminoethyl]-4-(4-acetylamino-2- methoxyphenylVpiperazine A mixture of 0.35 g of l-[N-cyclohexylcarbonyl-N-(2-pyridyl)-2-aminoethyl]-4-(4- amino-2-methoxyphenyl)-piperazine (prepared as described in Example 6), 5 ml of chloroform and 0.063 ml of acetyl chloride was stirred for 2.5 hours at room temperature.
  • This compound was prepared and purified by the method described in Example 7, but using methylsulphonyl chloride instead of acetyl chloride. Yield 75%.
  • This compound was prepared and purified by the method described in Example 1 1 , but using butanoyl chloride in place of pivaloyl chloride. Yield 53%.
  • EXAMPLE 14 l- ⁇ S[-cvclohexylcarbonyl-N-(2-pyridv ⁇ -2-aminoethyl1-4-( " 2.5-dichlorobenzyl)-piperazine methylsulphonate hemihvdrate 2.01 g of 2,5-dichlorobenzyl chloride was added to a mixture of 1.94 g 1- ethoxycarbonylpiperazine, 3.45 g anhydrous potassium carbonate and 20 ml of dimethylformamide, stirred at room temperature under a nitrogen atmosphere. After stirring for a further 24 hours at room temperature, the reaction mixture was poured into 200 ml of water and extracted with ethyl acetate (3 x 100 ml).
  • EXAMPLE 17 l-[N-cvclohexylcarbonyl-N-(2-pyridyl)-2-aminoethyl]-4-benzoylpiperazine This compound was prepared as described in Example 15, but using 1-benzoyl- piperazine (prepared as described by K.-R. Jacobi Chem. Ber. 1933, 113-116) in place of 1-benzylpiperazine. The crude was purified by flash chromatography (chloroform : methanol 97.5:2.5) affording 54% yield of the title product.
  • This compound was prepared as described in the final step of Example 1 , but using 1-benzoylmethyl-piperazine (prepared according to the procedure described in Beil. 23, V/2, 200) in place of l-(2-trifluoromethoxyphenyl)-piperazine.
  • the crude product was purified by flash chromatography (ethyl acetate -2N methanolic ammonia, gradient 97:3 to 95:5). The residue obtained by evaporation of the collected fractions was dissolved in ethyl acetate. An excess of 5N isopropanolic hydrogen chloride was added and the precipitate was collected by filtration to give the title compound, yield 18%. M.p. 225- 228°C dec.
  • rats were anaesthetised by subcutaneous injection of 1.25 g/kg (5 ml/kg) urethane, after which the urinary bladder was catheterised via the urethra using PE 50 polyethylene tubing filled with physiological saline.
  • the catheter was tied in place with a ligature around the external urethral orifice and was connected with conventional pressure transducers (Statham P23 ID/P23 XL).
  • the intravesical pressure was displayed continuously on a chart recorder (Battaglia Rangoni KV 135 with DCl/TI amplifier).
  • the bladder was then filled via the recording catheter by incremental volumes of warm (37°C) saline until reflex bladder voiding contractions occurred (usually 0.8-1.5 ml).
  • the potency of the tested compounds was evaluated on a quantal basis by the method of Bliss (Bliss C.I., Quart. J. Pharm. Pharmacol, ⁇ , 192-216, 1938).
  • Data represent mean values ⁇ S.E. of the duration of bladder quiescence (disappearance time of contractions in min after i.v. administration of compound).
  • Data represent mean values ⁇ S.E. of the duration of bladder quiescence (disappearance time of contractions in min after i.v. administration of compound).
  • Genomic clone G-21 coding for the human 5-HTiA-serotoninergic receptor is stably transfected in a human cell line (HeLa).
  • HeLa cells were grown as monolayers in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10 % fetal calf serum and gentamicin (100 mg/ml), 5% CO2 at 37°C. Cells were detached from the growth flash at 95% confluence by a cell scraper and were lysed in ice-cold 5 mM Tris and 5 mM EDTA buffer (pH 7.4).
  • DMEM Dulbecco's modified Eagle's medium
  • gentamicin 100 mg/ml
  • CO2 5% CO2
  • Membranes were incubated in a final volume of 1 ml for 30 min at 30°C with 0.2 - 1 nM [ H]8-OH-DPAT, in absence or presence of competing drugs; non-specific binding was determined in the presence of 10 mM 5-HT. The incubation was stopped by addition of ice-cold Tris-HCl buffer and rapid filtration through 0.2% polyethyleneimine pretreated Whatman GF/B or Schleicher & Schuell GF52 filters.
  • the compounds of the present invention have a high affinity for serotonergic 5-HT 1 A receptors. These results show that this receptor has a role in the action which the compounds of the invention exert on the bladder.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des composés de la formule (I) (dans laquelle n = 1 ou 2, Het = hétéroaryle monocyclique, R = cycloalkyle ou hétéroaryle monocyclique, R3 = H ou alkyle inférieur, Z = liaison, -CH2-, -CH2CH2-, -CH2C(O)-, -CH2CH(OH)-, -O-, -OCH2- ou -C(O)-, B = aryle ou hétéroaryle substitué ou non substitué), lesquels se lient à des récepteurs 5HT1A et sont par conséquent utiles dans le traitement des dysfonctionnements neuro-musculaires du tractus urinaire inférieur. L'invention se rapporte aux composés dans lesquels Z = liaison, B = un groupe phényle substitué de la formule (a) (dans laquelle R1 = H, halogène, alcoxy, NO2, NH2, NH(acyle), NHSO2(alkyle), R2=halogène, alcoxy, polyfluoroalcoxy, CN, CONH2; à condition que lorsque R1 NH(acyle) ou NHSO2(alkyle), alors R2 = polyfluoroalcoxy) et aux composés dans lesquels Z = -CH2-, -CH2CH2-, -CH2C(O)-, -CH2CH(OH)-, -O-, -OCH2- ou -C(O)-, en eux-mêmes, et à d'autres composés utilisés dans la préparation de médicaments destinés à traiter les dysfonctionnements neuro-musculaires du tractus urinaire inférieur.
EP98945130A 1997-08-01 1998-07-31 Piperazines 1,4-disubstituees Withdrawn EP1000045A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI971863 1997-08-01
ITMI971862 1997-08-01
ITMI971863 IT1293806B1 (it) 1997-08-01 1997-08-01 Ammidoalchilpiperazine attive sulle basse vie urinarie
ITMI971862 IT1293805B1 (it) 1997-08-01 1997-08-01 Piperazine 1,4-disostituite
PCT/EP1998/004796 WO1999006382A1 (fr) 1997-08-01 1998-07-31 Piperazines 1,4-disubstituees

Publications (1)

Publication Number Publication Date
EP1000045A1 true EP1000045A1 (fr) 2000-05-17

Family

ID=26331533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98945130A Withdrawn EP1000045A1 (fr) 1997-08-01 1998-07-31 Piperazines 1,4-disubstituees

Country Status (4)

Country Link
EP (1) EP1000045A1 (fr)
JP (1) JP2001512110A (fr)
AU (1) AU9256498A (fr)
WO (1) WO1999006382A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271234B1 (en) 1997-08-01 2001-08-07 Recordati S.A., Chemical And Pharmaceutical Company 1,4-disubstituted piperazines
US6906069B1 (en) 1999-01-08 2005-06-14 Amgen Inc. LXR modulators
US6306861B1 (en) 1999-07-30 2001-10-23 Recordati S.A. Chemical And Pharmaceutical Company Thienopyrancecarboxamide derivatives
US6387909B1 (en) 1999-07-30 2002-05-14 Recordati S.A. Chemical And Pharmaceutical Company Thienopyranecarboxamide derivatives
IT1313581B1 (it) * 1999-07-30 2002-09-09 Recordati Chem Pharm Derivati tienopirancarbossamidici.
US6403594B1 (en) 1999-10-18 2002-06-11 Recordati, S.A. Chemical And Pharmaceutical Company Benzopyran derivatives
IT1314192B1 (it) * 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati benzopiranici
WO2001060818A1 (fr) * 2000-02-14 2001-08-23 Tularik Inc. Modulateurs lxr
US6673543B2 (en) 2000-04-05 2004-01-06 Tularik, Inc. Solid phase synthesis of LXR ligands
ITMI20012060A1 (it) * 2001-10-05 2003-04-05 Recordati Chem Pharm Nuovi eterocilcli n-acilati
US7112606B2 (en) 2002-01-30 2006-09-26 Amgen Inc. Heterocyclic arylsulfonamidobenzylic compounds
ITMI20021328A1 (it) * 2002-06-14 2003-12-15 Recordati Ind Chimica E Farma Nuove piperazine 1,4 - disostituite
US7071197B2 (en) 2002-06-14 2006-07-04 Recordati S.A. N,N-disubstituted diazocycloalkanes
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
CN117003693A (zh) * 2022-05-05 2023-11-07 四川大学华西医院 一类哌啶衍生物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645681B2 (en) * 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
GB9306103D0 (en) * 1993-03-24 1993-05-12 Wyeth John & Brother Ltd Piperazine derivatives
IT1266582B1 (it) * 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
GB9411099D0 (en) * 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9906382A1 *

Also Published As

Publication number Publication date
JP2001512110A (ja) 2001-08-21
AU9256498A (en) 1999-02-22
WO1999006382A1 (fr) 1999-02-11

Similar Documents

Publication Publication Date Title
EP1000047B1 (fr) Derives de 1-(n-phenylaminoalkyl)-piperazine substitues a la position 2 du cycle phenyle
WO1999006382A1 (fr) Piperazines 1,4-disubstituees
US4547505A (en) N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
US4562201A (en) Aminomethyl benzanilides
CA2606262C (fr) Nouveaux ligands recepteurs histaminiques h3 et leurs applications therapeutiques
BG107789A (bg) Амидоалкилпиперидинови и амидоалкилпиперазинови производни, приложими за лечение на заболявания на нервната система
EP1000046B1 (fr) Derives piperazines agissant sur les voies urinaires inferieures
CA2376819C (fr) Derives de 2-aminoindane utilises comme agents anesthesiques cutanes
US6399614B1 (en) 1-(N-phenylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring
US6271234B1 (en) 1,4-disubstituted piperazines
US20020193383A1 (en) 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring
US4748184A (en) Aryl substituted aminomethyl benzene derivatives having antiarrhythmic utility
CN101312961A (zh) 异喹啉与苯并[h]异喹啉衍生物，它们的制备及其作为组胺h3受体拮抗药的治疗用途
US4755527A (en) Aryl substituted aminomethyl benzene derivatives
US5837717A (en) Hydroxamic acid anesthetic compounds
US4923873A (en) Quinazoline substituted aminomethyl benzene derivatives
CA2489450A1 (fr) Diazocycloalcanes n,n-disubstitues utiles dans le traitement de troubles du systeme nerveux central dus a un dysfonctionnement serotoninergique
MXPA00000943A (en) 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring
FR2717174A1 (fr) Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes.
IL114388A (en) Use of 2-amino-n-(1,2-diphenyl-1-methylethyl) acetamide and salts thereof in the manufacture of neuroprotective pharmaceutical compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000221;LT PAYMENT 20000221;LV PAYMENT 20000221;MK PAYMENT 20000221;RO PAYMENT 20000221;SI PAYMENT 20000221

17Q First examination report despatched

Effective date: 20020610

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030423